sirolimus inhaled (LAM-001) / OrphAI Therapeutics - LARVOL DELTA

LAM-001 for the Treatment of Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD) (clinicaltrials.gov) - P2 | N=85 | Recruiting | Sponsor: OrphAI Therapeutics | Active, not recruiting ➔ Recruiting

Enrollment open • Cardiovascular • Hypertension • Interstitial Lung Disease • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

LAM-001 for the Treatment of Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD) (clinicaltrials.gov) - P2 | N=85 | Active, not recruiting | Sponsor: OrphAI Therapeutics | N=10 ➔ 85 | Trial completion date: Sep 2027 ➔ Aug 2028 | Trial primary completion date: May 2025 ➔ Jul 2027

Enrollment change • Trial completion date • Trial primary completion date • Cardiovascular • Hypertension • Interstitial Lung Disease • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

An Open Label Phase 2a Exploratory Study of Inhaled Sirolimus (LAM-001) for the Treatment of Pulmonary Hypertension (ATS 2026) - No abstract available

Clinical • P2a data • Cardiovascular • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

A Phase 2a Study of LAM-001 for the Treatment of Pulmonary Hypertension (clinicaltrials.gov) - P2 | N=10 | Active, not recruiting | Sponsor: OrphAI Therapeutics | Recruiting ➔ Active, not recruiting | N=15 ➔ 10 | Trial completion date: Oct 2026 ➔ Sep 2027 | Trial primary completion date: Sep 2025 ➔ May 2025

Enrollment change • Enrollment closed • Trial completion date • Trial primary completion date • Cardiovascular • Hypertension • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

A Phase 2a Study of LAM-001 for the Treatment of Pulmonary Hypertension (clinicaltrials.gov) - P2 | N=15 | Recruiting | Sponsor: OrphAI Therapeutics | Trial completion date: Dec 2025 ➔ Oct 2026 | Trial primary completion date: Dec 2024 ➔ Sep 2025

Trial completion date • Trial primary completion date • Cardiovascular • Hypertension • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

INSPO-BOS: LAM-001 in Lung Transplant Recipients With Bronchiolitis Obliterans Syndrome. (clinicaltrials.gov) - P2 | N=30 | Recruiting | Sponsor: Steven Hays, MD | Trial completion date: Dec 2025 ➔ Oct 2026 | Trial primary completion date: Dec 2025 ➔ Oct 2026

Trial completion date • Trial primary completion date • Pulmonary Disease • Respiratory Diseases • Transplantation

A Phase 2a Study of LAM-001 for the Treatment of Pulmonary Hypertension (clinicaltrials.gov) - P2 | N=15 | Recruiting | Sponsor: OrphAI Therapeutics | Phase classification: P2a ➔ P2

Phase classification • Cardiovascular • Hypertension • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

A Phase 2a Study of LAM-001 for the Treatment of Pulmonary Hypertension (clinicaltrials.gov) - P2a | N=15 | Recruiting | Sponsor: OrphAI Therapeutics | Trial completion date: Feb 2025 ➔ Dec 2025 | Trial primary completion date: Feb 2024 ➔ Dec 2024

Trial completion date • Trial primary completion date • Cardiovascular • Hypertension • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

INSPO-BOS: Inhaled Sirolimus in Lung Transplant Recipients With Bronchiolitis Obliterans Syndrome. (clinicaltrials.gov) - P2 | N=30 | Recruiting | Sponsor: Steven Hays, MD

New P2 trial • Pulmonary Disease • Respiratory Diseases • Transplantation